Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: Results from the Phase 3 ELEVATE UC clinical programme
JJC 2024;18;391(3):2170 82. DOI 10.1093/ecco-jcc/jjae038
Peyrin-Biroulet et al. evaluated the efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis, demonstrating significant improvement in clinical outcomes compared to placebo. The study reported a favourable safety profile, making etrasimod a viable treatment option for this population.
The Phase 3 ELEVATE UC clinical programme focused on patients with isolated proctitis, aiming to assess both therapeutic efficacy and long-term safety. The trial provided robust evidence supporting the use of etrasimod, particularly highlighting its impact on improving remission rates and symptom control.
